Ifenprodil inhibits nicotine-induced addiction-like behaviors in mice
Life Sciences · 2026
DOI: 10.1016/j.lfs.2025.124116 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Sciences, 2026. Verfasst von Soichiro Ide und 6 weiteren Autor:innen. Beteiligte Einrichtung: Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan. Electronic add…. Hauptthemen laut MEDLINE: Adrenergic alpha-Antagonists, Excitatory Amino Acid Antagonists, Nicotine, Behavior, Addictive. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Tokyo Medical and Dental University, Smoking Research Foundation, Japan Society for the Promotion of Science.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Nicotine addiction remains a global public health problem, with high relapse rates and limited long-term success from current treatments. This highlights the need for new therapeutic strategies that target novel mechanisms of nicotine addiction. Ifenprodil, a GluN2B-containing N-methyl-d-aspartate receptor antagonist and G protein-activated inwardly rectifying potassium inhibitor, among other actions, potentially offers a new approach. The present study investigated the efficacy of ifenprodil in reducing nicotine-induced addiction-like behaviors. We evaluated effects of systemic ifenprodil administration on nicotine-induced behaviors in mice using two experimental paradigms: a lateral hypothalamus intracranial self-stimulation (lhICSS) test using a rate-frequency procedure and a two-bottle choice preference test. Dopamine transporter (DAT) knockout (KO) and wild-type mice were used to investigate nicotine's effects on reward-related behavior. Nicotine and ifenprodil were delivered via intraperitoneal injection. In wild-type mice, acute nicotine (0.1-1.0 mg/kg) had no significant effect on lhICSS rates across stimulation frequencies, although a low dose (0.1 mg/kg) produced a modest increase. The 0.1 mg/kg dose of nicotine but not higher doses (0.3 or 1.0 mg/kg) significantly enhanced lhICSS rates in DAT-KO mice. Pretreatment with ifenprodil (1-10 mg/kg) dose-dependently reduced the nicotine-induced enhancement of reward in DAT-KO mice. In wild-type males, ifenprodil acutely decreased nicotine preference in the two-bottle choice test following chronic nicotine exposure. These findings indicate that ifenprodil suppresses nicotine-related behaviors primarily in mice on a hyperdopaminergic (DAT-KO) background. Although further validation in wild-type models is warranted to clarify the translational generalizability of these findings, ifenprodil may be a novel approach for the treatment of nicotine addiction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan. Electronic address: ide-si@igakuken.or.jp.
- Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan; Research Center for Advanced Science and Technology, The Univ…
- Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan.
- Departments of Neurology and Pharmacology, University of Maryland School of Medicine, and VA Maryland Healthcare System, 655 W. Baltimore Street, Baltimore, MD, 21201, USA.
- Department of Digital Psychiatry, Kobe University Graduate School of Medicine, Kobe Biotechnology Center, 1-5-6 Minatojima Minamimachi, Chuo Ward, Kobe, 650-0047, Japan.
- Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.
Förderung
- Tokyo Medical and Dental University
- Smoking Research Foundation
- Japan Society for the Promotion of Science
- Tamura Science and Technology Foundation
Zitieren
APA
Ide, S., Izuo, N., Ikekubo, Y., Uhl, G. R., Sora, I., Nitta, A., & Ikeda, K. (2026). Ifenprodil inhibits nicotine-induced addiction-like behaviors in mice. Life Sciences. https://doi.org/10.1016/j.lfs.2025.124116
Vancouver
Ide S, Izuo N, Ikekubo Y, Uhl GR, Sora I, Nitta A, et al. Ifenprodil inhibits nicotine-induced addiction-like behaviors in mice. Life Sciences. 2026. doi:10.1016/j.lfs.2025.124116
BibTeX
@article{Ide2026,
author = {Ide, Soichiro and Izuo, Naotaka and Ikekubo, Yuiko and Uhl, George R and Sora, Ichiro and Nitta, Atsumi and Ikeda, Kazutaka},
title = {Ifenprodil inhibits nicotine-induced addiction-like behaviors in mice},
journal = {Life Sciences},
year = {2026},
doi = {10.1016/j.lfs.2025.124116}
}
EUVIMED